Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com/ and get exclusive access to our numerous stock reports.
Raptor Pharmaceutical Corp. (NASDAQ: RPTP) shares declined 1.89 percent to close at $14.51 a share Wednesday. The stock traded between $14.41 and $14.99 on volume 1.05 million shares traded. FBR Capital analysts have recently initiated coverage on the company with an "outperform" rating. Shares of Raptor Pharmaceutical have gained approximately 148.0 percent year-to-date.
Get more information on Raptor Pharmaceutical and free access to the in-depth equity report at:
www.FiveStarEquities.com/RPTP
Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares declined 7.78 percent to close at $38.63 a share Wednesday. The stock traded between $38.04 and $41.66 on volume of 2.86 million shares traded. FBR Capital analysts have recently initiated coverage on the company with a "market perform" rating. Shares of Sarepta Therapeutics have gained approximately 50.0 percent year-to-date.
Get more information on Sarepta Therapeutics and free access to the in-depth equity report at:
www.FiveStarEquities.com/SRPT
Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) shares gained 2.69 percent to close at $6.86 a share Wednesday. The stock traded between $6.76 and $7.21 on volume of 615,635 shares traded. FBR Capital analysts have recently initiated coverage on the company with an "outperform" rating. Shares of Supernus Pharmaceuticals have fallen approximately 4.0 percent year-to-date.
Get more information on Supernus Pharmaceuticals and free access to the in-depth equity report at:
www.FiveStarEquities.com/SUPN
Valeant Pharmaceuticals Intl Inc. (NYSE: VRX)(TSX: VRX) shares declined 1.80 percent to close at $109.06 a share Wednesday. The stock traded between $107.74 and $111.93 on volume 1.54 million shares traded. FBR Capital analysts have recently initiated coverage on the company with an "outperform" rating. Shares of Valeant Pharmaceuticals have gained approximately 82.0 percent year-to-date.
Get more information on Valeant Pharmaceuticals free access to the in-depth equity report at:
www.FiveStarEquities.com/VRX
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Five Star Equities
[email protected]